← Back to Search

Diuretic

KMgCit + Chlorthalidone for High Blood Pressure

N/A

Waitlist Available

Led By Wanpen Vongpatanasin, MD

Research Sponsored by University of Texas Southwestern Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

• Treated or untreated stage I hypertension

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 4 to week 16

Awards & highlights

Study Summary

This trial will test if a potassium magnesium citrate supplement can help offset some of the adverse metabolic effects of chlorthalidone, beyond just correcting for hypokalemia.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 4 to week 16

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 4 to week 16

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 to week 16 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Fasting Plasma Glucose From Week 4 to Week 16

Secondary outcome measures

Chang in Hepatic Fat Measured at Baseline and Week 16

Change in FGF23 From Week 4 to Week 16

Change in Muscle Magnesium Content Measured at Baseline and Week 16

Trial Design

2Treatment groups

Active Control

Group I: KMgCit + ChlorthalidoneActive Control2 Interventions

After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KMgCit for 4 months.

Group II: KCl + ChlorthalidoneActive Control2 Interventions

After a run-in period of 2-3 weeks on Chlorthalidone, patients will be randomized to the addition of KCl for 4 months.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of Texas Southwestern Medical CenterLead Sponsor

1,047 Previous Clinical Trials

1,053,738 Total Patients Enrolled

Wanpen Vongpatanasin, MDPrincipal Investigator - UT Southwestern Medical Center

Children's Medical Center of Dallas, The University of Texas Southwestern Medical Center At Dallas, UT Southwestern Medical Center-Zale Lipshy Campus

Chulalongkorn University (Medical School)

University Tx Southwestern Medical Sch (Residency)

11 Previous Clinical Trials

779 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there still an opportunity to participate in this experiment?

"According to information hosted on clinicaltrials.gov, the trial is actively searching for eligible patients and has been doing so since its inception in January of 2015. The particulars were last revised on February 10th 2022."

Answered by AI

How many people are participating in this experiment?

"Affirmative. Clinicaltrials.gov provides evidence that the trial, which was first published on January 1st 2015, is currently enrolling participants. Sixty individuals from three distinct medical facilities will be participating in this study."

Answered by AI

What therapeutic effects does the drug combination of KCl and Chlorthalidone provide?

"Typically, KCl + Chlorthalidone is prescribed to manage edema-related issues. It can also be efficacious in treating kidney diseases, terminal state conditions, and urine alkalinization therapy."

Answered by AI

What other research efforts have been conducted to study the effects of KCl + Chlorthalidone?

"Presently, there are 27 ongoing clinical trials for KCl + Chlorthalidone with 4 at Phase 3. While many of the studies are located in Dallas, Texas, 113 medical centres across America are conducting research involving this medication."

Answered by AI